Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;8(5):409-413.
doi: 10.21037/tau.2019.09.19.

Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045")

Mayer Fishman  1   2   3
Affiliations
Editorial

Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045")

Mayer Fishman. Transl Androl Urol. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has participated in trials sponsored by the manufacturers of pembrolizumab (Merck), nivolumab (BMS), atezolizumab (Roche), durvalumab (AstraZeneca), avelumab (EMD Serono), enfortumab vedotin (Seattle Genetics) lenvatinib (Eisai) and everolimus (Novartis); promotional programs sponsored through EMD Serono, Pfizer, Exelixis. Advisory boards relating to avelumab (Pfizer and EMD Serono), pembrolizumab (Eisai/Merck), enfortumab vedotin (Astellas/SeattleGenetics).

Figures

Figure 1
Figure 1
Stylized OS curve (solid) and PFS curve (dotted) showing a segmentation of the response population with segment (A)—about 40–50%—with no significant difference of OS nor of PFS evident, each shown as a single line representing either the natural history of the cancer or a uniform treatment effect. Segment (B), about 25–30% of the population showing no significant difference of PFS (dotted red line) but growing OS differences, including (I) significant OS difference (10.1 vs. 7.3 months) at the median, and (II) the 12 months landmark OS difference (44.2% vs. 29.8%). Segment (C), the remainder of the population for which there is the biggest clinical impact, with much larger improvement of both OS (blue) and PFS, with (III) landmark 12 months PFS 18.2% vs. 9.9%; (IV) landmark 24 months OS 26.9% vs. 14.3%; and (V) landmark 24 months PFS (12.4% vs. 3%). OS, overall survival; PFS, progression free survival.
See this image and copyright information in PMC

Comment on

References

    1. Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTE-045 Investigators Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015-26. 10.1056/NEJMoa1613683 - DOI - PMC - PubMed
    1. Yagoda A, Watson RC, Gonzalez-Vitale JC, et al. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat Rep 1976;60:917-23. - PubMed
    1. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 2019. [Epub ahead of print]. 10.1093/annonc/mdz127 - DOI - PMC - PubMed
    1. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748-57. 10.1016/S0140-6736(17)33297-X - DOI - PubMed
    1. Burgess EF, Livasy C, Hartman A, et al. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol 2019;37:299.e19-299.e25. 10.1016/j.urolonc.2019.01.002 - DOI - PubMed